Clinical Trial 90038

• Overview

  Study Title:

  A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.